All In Biotech

Drug Trial Radar · NCT05597917

tTF-NGR Randomized Study - STS

Phase III Study Comparing Trabectedin (T) Versus T Plus tTF-NGR to Entrap T Inside the Tumor in Patients With Metastatic and/or Refractory Soft Tissue Sarcoma (STS)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Oct 26, 2021

Primary completion

Dec 2030

Study completion Jun 2031

Sponsor

Lead sponsor
Universität MünsterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Anturec Pharmaceuticals GmbH
First posted
Oct 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this phase III open label, controlled clinical trial patients with unresectable or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs and CD13 positivity in central histology (grade \>/= 1+) are treated to evaluate whether tTF-NGR in combination with standard trabectedin chemotherapy prolongs progression-free survival (according to iRECIST), as compared with trabectedin alone. Further objectives are to evaluate the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy with respect to the response rate and overall survival as well as to assess the safety profile of tTF-NGR combined with trabectedin. Before the randomized phase III part of the study, there was a safety run-in part. The final dose of tTF-NGR established as safe in this safety run-in part is 0.5 mg/m2 per day for 2 consecutive days following each trabectedin infusion and is used for the randomized (parallel 1:1; Arm 1: standard trabectedin, Arm 2: standard trabectedin plus tTF-NGR) phase III part of this trail. . Further dose modification for tTF-NGR is possible.

Conditions

  • Soft Tissue Sarcoma

Interventions

  • TrabectedinDrug

    Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.

  • tTF-NGRBiological

    Patients will receive standard trabectedin according to arm 1 plus 0.5 mg/m2 f tTF-NGR (1-hour rate-controlled infusion, port or central venous access, 0.9 % NaCl ad 100 mL) on days 2 and 3 following each trabectedin cycle (within max 2 hours interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 10 am and on the following day, q d 22 x until disease progression or contraindications against further application. Further dose modification for tTF-NGR is possible (see chapter 6.1.4 of the protocol).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: Prolongation of progression-free survival (PFS) according to iRECIST as judged by central radiology in a blinded fashion after end of trial.Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Universitätsklinikum Augsburg

    Augsburg, Germany · Recruiting

  • HELIOS Klinikum Bad Saarow

    Bad Saarow, Germany · Recruiting

  • HELIOS Klinikum Berlin-Buch

    Berlin, Germany · Recruiting

  • TU Dresden Medizinische Fakultät Carl Gustav Carus

    Dresden, Germany · Recruiting

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany · Recruiting

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Medizinische Hochschule Hannover

    Hanover, Germany · Recruiting

  • Universitätsklinikum Heidelberg

    Heidelberg, Germany · Recruiting

  • Universitätsklinikum Jena

    Jena, Germany · Recruiting

  • Universitätsklinikum Leipzig

    Leipzig, Germany · Recruiting

  • Universitätsmedizin Mainz

    Mainz, Germany · Recruiting

  • LMU Klinikum

    München, Germany · Recruiting

  • Klinikum rechts der Isar der technischen Universität München

    München, Germany · Recruiting

  • University Hospital Muenster, Germany

    Münster, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.